ÐÓ°ÉÂÛ̳

Skip to main content
Quest Diagnostics

SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent ÐÓ°ÉÂÛ̳-19-Related Outcomes

Authors:?Kaufman HW, Letovsky S, Meyer WA III,? Gillim L, Assimon MM, Kabelac CA, Kroner JW, Reynolds SL, Eisenberg M

Citation: Front Public Health. 2023;11. doi:10.3389/fpubh.2023.1193246

Specialties:?Infectious disease, ÐÓ°ÉÂÛ̳-19, Immunology

Download key summary

Related content

Test FAQ
SARS CoV 2 Antibody Testing
On-Demand Webinar
Combating ÐÓ°ÉÂÛ̳-19 ¨C Monoclonal Antibody Therapies to Optimize Patient Care
Publication
Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022
Publication
Assessing vulnerability to ÐÓ°ÉÂÛ̳ 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Publication
Detection of SARS CoV 2 IgG Targeting Nucleocapsid or Spike Protein by Four High Throughput Immunoassays Authorized for Emergency Use

Our company

Quest? is the brand name used for services offered by ÐÓ°ÉÂÛ̳ and its affiliated companies. ÐÓ°ÉÂÛ̳ and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.? Other affiliates operated under the Quest? brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.?

?

Quest?, Quest Diagnostics?, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks¡ª? and ?¡ªare the property of their respective owners. ? 2025 ÐÓ°ÉÂÛ̳. All rights reserved. Image content features models and is intended for illustrative purposes only.